The last issue we want to tackle here is the challenge for designing specific and efficient inhibitors of each of the 16 JNK isoforms, usable in therapy without cytotoxicity, for example to treat neuropathies or cancer (for review [199]. This evidence concerns the gene MAPK8 and cancer.